Erlotinib Synthesis via Single-Step Reflux
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current processes for preparing erlotinib and its salts are not consistently efficient, safe, time-consuming, and often involve the use of corrosive chemicals, limiting their commercial viability and purity.
Innovation Solution
A novel process involving the direct reaction of 2-amino-4,5-bis(2-methoxyethoxy) benzonitrile with 3-ethynyl aniline and a compound like triethyl orthoformate, using an acid catalyst, in a single step, under reflux conditions, avoiding the use of corrosive chemicals like phosphorus oxychloride/thionyl chloride.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional processes using phosphorus oxychloride/thionyl chloride are used, then erlotinib can be prepared, but the process involves corrosive chemicals that reduce safety and increase handling risks
Solution Approach 1:
The patent removes the harmful corrosive chemicals (phosphorus oxychloride/thionyl chloride) from the synthesis process entirely, replacing them with safer reagents while maintaining the ability to produce erlotinib and its salts
Solution Approach 2:
The patent converts the harmful corrosive chemistry into a safer alternative process using mild reagents, transforming a hazardous process into a safe and commercially viable manufacturing method
2Productivity
If multi-step processes are used, then erlotinib can be prepared with adequate purity, but the process is time-consuming and reduces productivity
Solution Approach 1:
The patent combines multiple synthesis steps into a single-step process where 2-amino-4,5-bis(2-methoxyethoxy)benzonitrile reacts directly with 3-ethynylaniline in the presence of triethyl orthoformate and acid catalyst to form erlotinib, eliminating intermediate purification steps while maintaining product purity
Solution Approach 2:
The patent uses pre-synthesized 2-amino-4,5-bis(2-methoxyethoxy)benzonitrile as a starting material that has been prepared in advance through optimized routes, allowing the final coupling reaction to proceed directly to high-purity product without intermediate purification
3Ease of manufacture
If corrosive chemicals are used, then the reaction can proceed effectively, but the process becomes less commercially viable due to safety concerns
Solution Approach 1:
The patent extracts and removes the corrosive chemical components from the reaction system, replacing them with non-corrosive reagents like triethyl orthoformate and mild acid catalysts, thereby eliminating handling risks while maintaining commercial viability
Solution Approach 2:
The patent employs readily available, non-hazardous reagents that can be handled without special precautions, making the process more accessible for commercial manufacturing without requiring specialized safety infrastructure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process results in a more efficient, safer, and commercially viable method for producing erlotinib and its salts with greater purity, reducing handling risks and time, while eliminating the need for hazardous chemicals.
Implementation Method 1
The reaction mixture is concentrated and then heated under reflux for 4-6 hours
Implementation Method 2
Concentrated hydrochloric acid is added to it. The resulting mixture is granulated at 20°C to 25°C to crystallize the product
Data Source
AI summary
The present invention relates to a process for preparation of erlotinib of Formula I or its pharmaceutically acceptable salt thereof. The present invention also relates to process for the preparation of erlotinib trifluoroacetate. The present invention also relates to a noveICrystalline form of erlotinib trifluoroacetate designated as Form E and process for its preparation. The present invention further relates to process for the preparation of erlotinib hydrochloride from erlotinib trifluoroacetate.